Randox Laboratories introduces PSA, BNP control
May 12, 2023—Randox Labs has released two new products, a prostate-specific antigen and brain natriuretic peptide control.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Randox Laboratories
Randox releases MRSA/MSSA PCR test on Vivalytic system
Oct. 7, 2022—Randox Laboratories has added its MRSA/SA test to the Vivalytic system.
Rapid COVID test available on Randox-Bosch Vivalytic
March 2021—A rapid coronavirus test that provides results for COVID-19 in 39 minutes is available on the Vivalytic, a point-of-care platform by Randox Laboratories and Bosch. The CE-approved test has a sensitivity of 98 percent and a specificity of 100 percent.
Randox SARS-CoV-2 antibody control
February 2021—Randox introduced its Acusera SARS-CoV-2 Antibody Control with reactive and nonreactive controls for anti SARS-CoV-2 to support assay validation and routine performance monitoring of serological assays for COVID-19. The third-party control is supplied in a liquid, ready-to-use format with a 30-day open vial stability at 2° to 8°C.
Reduced TAT for Vivalytic SARS-CoV-2 positive samples
February 2021—Randox announced that its improved software for the Vivalytic analysis device enables its CE-marked Vivalytic SARS-CoV-2 rapid coronavirus test to deliver results for positive samples in less than 30 minutes.
Randox multiplex controls for respiratory disease
January 2021—Randox Laboratories has unveiled its Qnostics Multiplex Respiratory Pathogen Controls for respiratory diseases, including for SARS-CoV-2, influenza A and B, and respiratory syncytial virus. The RTX controls are used to monitor the full testing process, from extraction to amplification and detection, and are compatible with a majority of commercial and in-house assays.
Reduced TAT for Vivalytic SARS-CoV-2 positive samples
Dec. 21, 2020—Randox announced that its improved software for the Vivalytic analysis device enables its CE-marked Vivalytic SARS-CoV-2 rapid coronavirus test to deliver results for positive samples in less than 30 minutes.
Randox whole pathogen controls for respiratory disease
Oct. 29, 2020—Randox Laboratories has unveiled its Qnostics Multiplex Respiratory Pathogen Controls for respiratory diseases, including for SARS-CoV-2, influenza A and B, and respiratory syncytial virus.
Randox unveils cytokine tests
August 2020—Randox Laboratories has unveiled cytokine testing for COVID-19 risk stratification and treatment monitoring. The tests look for the presence of cytokines and are performed using Randox’s Biochip technology, which can detect up to 12 cytokines and growth factors from a single patient sample. The testing menu includes 26 cytokines across four biochip panels.
Randox QC for ToRCH test gets CE mark
July 2020—Randox Laboratories ToRCH quality controls for infectious disease testing in newborns have been granted the CE mark.